預防及治療抗腫瘤化學療法與抗腫瘤放射線療法引起的噁心、嘔吐。

Antiemetic; Selective 5-HT3 Receptor Antagonist

Duration: 24 hours.
Distribution: 2 to 4 L/kg.
Protein binding: ~65%.
Metabolism: Hepatic via CYP1A1 and CYP3A4 N-demethylation, oxidation, and conjugation; some metabolites may have 5-HT3 antagonist activity.
Half-life elimination: 6 hours.
Excretion: Urine ; feces.

Hypersensitivity to granisetron or any component of the formulation or to other 5-HT3 receptor antagonists.

B

>10%: Constipation (3% to 22%), nausea (20%), vomiting (12%), injection site reaction, asthenia (14% to 18%), headache (9% to 21%).
1% to 10%: hypertension (1% to 2%), prolonged QT interval on ECG (1% to 3%), alopecia (3%), abdominal pain (4% to 7%), decreased appetite (6%), diarrhea (4% to 9%), dyspepsia (3% to 6%), anemia (4%), leukopenia (9%), thrombocytopenia (2%), increased serum alanine aminotransferase (3% to 6%), increased serum aspartate aminotransferase (3% to 5%),anxiety (≤2%), dizziness (3% to 5%), drowsiness (≤4%), insomnia (4% to 5%),fever (3% to 9%).

Chemotherapy-induced nausea and vomiting (CINV), prevention:
2 mg once a day. The first dose should be given within one hour of treatment.
Radiation therapy–associated emesis, prophylaxis:
2 mg once daily administered 1 to 2 hours prior to each fraction of radiation; administer in combination with dexamethasone.

For infants, Children, and Adolescents: 40 mcg/kg/dose every 12 hours on chemotherapy days.

Children ≥ 2 years and Adolescents: No dosage adjustment necessary.